106791-93-9

Basic information

• Product Name: 2-Pyrimidinamine, 5-bromo-4-chloro-6-phenyl-
• Synonyms: 2-Pyrimidinamine,5-bromo-4-chloro-6-phenyl;2-amino-5-bromo-4-chloro-6-phenylpyrimidine;F2158-1071;5-bromo-4-chloro-6-phenyl-2-pyrimidinamine
• CAS NO: 106791-93-9
• Molecular Formula: C10H7BrClN3
• Molecular Weight: 284.543
• Mol File: 106791-93-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-Pyrimidinamine, 5-bromo-4-chloro-6-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyrimidinamine, 5-bromo-4-chloro-6-phenyl-(106791-93-9)
• EPA Substance Registry System: 2-Pyrimidinamine, 5-bromo-4-chloro-6-phenyl-(106791-93-9)

Safety Data

• Hazardous Substances Data: 106791-93-9(Hazardous Substances Data)

Upstream product

• 98-80-6 phenylboronic acid 
• 56741-95-8 bropirimine 
• 36314-97-3 4-chloro-6-phenylpyrimidin-2-amine 

Downstream Products

• 282543-44-6 2-amino-4-methoxy-5-(4-methoxyphenyl)-6-phenylpyrimidine 
• 282543-41-3 2-amino-4-methoxy-5,6-diphenylpyrimidine 
• 282543-40-2 2-amino-5-iodo-4-methoxy-6-phenylpyrimidine 
• 36315-02-3 4-methoxy-6-phenylpyrimidin-2-ylamine 
• 66376-75-8 2-amino-5,6-diphenylpyrimidin-4(3H)-one 
• 282543-39-9 2-amino-5-bromo-4-methoxy-6-phenylpyrimidine 

Relevant articles and documents

TRIAZOLE COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONISTS

Described herein are triazole compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.

HETEROARYL[4,3-C]PYRIMIDINE-5-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF

A heteroaryl[4,3-c]pyrimidin-5-amine derivative, a preparation method therefor, and medical uses thereof. Specifically, a heteroarylo[4,3-c]pyrimidin-5-amine derivative represented by a general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and uses thereof as therapeutic agents, in particular, a use as a A2a receptor antagonist and A use in preparation of a medicament for treatment of conditions or symptoms that are ameliorated by inhibiting the A2a receptor; various substituent groups in the general formula (I) have the identical meanings as those in the specification.

4-substituted-6-aryl-pyrimidine compounds

This invention describes the synthesis and anti-neoplastic use of 4-aziridyl-5-substituted/unsubstituted 6-aryl-pyrimidine compounds of Formula IA STR1 as well as N'-[2-(1-aziridyl)ethyl]-6-aryl-2,4-pyrimidinediamines of Formula IB STR2 and 4-chloro or bromo-5-substituted/unstubstituted-6-aryl-pyrimidines.